Comparative Pharmacology
Head-to-head clinical analysis: IODOHIPPURATE SODIUM I 131 versus SALPIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IODOHIPPURATE SODIUM I 131 versus SALPIX.
IODOHIPPURATE SODIUM I 131 vs SALPIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodohippurate sodium I 131 is a radioactive diagnostic agent that is actively transported by the renal tubules, allowing imaging of renal morphology and function. The iodine-131 emits gamma radiation, enabling scintigraphic evaluation of renal blood flow, tubular secretion, and excretion.
SALPIX (sodium chloride 0.9%, benzyl alcohol 0.9%) is a sterile, nonpyrogenic isotonic solution. It does not have a direct pharmacological mechanism of action; it is used as a vehicle or diluent for other medications and for irrigation. The benzyl alcohol component acts as a bacteriostatic preservative.
Adult: 5-30 microcuries (0.185-1.11 MBq) intravenously for renal function studies.
SALPIX (hysterosalpingography contrast medium) is administered intrauterine as a single dose of 10-20 mL, instilled slowly under fluoroscopic guidance. No systemic dosing; procedure is diagnostic.
None Documented
None Documented
Terminal elimination half-life is approximately 60 minutes in patients with normal renal function. In renal impairment, half-life may be prolonged up to several hours, correlating with reduced clearance.
Terminal elimination half-life: 1.5–2.0 hours. Short half-life necessitates frequent dosing in clinical use.
Primarily renal; >90% of administered dose excreted unchanged in urine within 24 hours via glomerular filtration and tubular secretion. Fecal excretion <2%.
Primarily renal excretion as unchanged drug: >90% within 24 hours. Minor biliary/fecal elimination (<10%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical